• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Goeddel David V returned 22,008,593 shares to the company and acquired 1,000 shares, closing all direct ownership in the company (SEC Form 4)

    4/8/24 8:02:22 PM ET
    $NGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GOEDDEL DAVID V

    (Last) (First) (Middle)
    1 LETTERMAN DRIVE
    BUILDING D, SUITE DM-900

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NGM BIOPHARMACEUTICALS INC [ NGM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/05/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/05/2024 D 134,180 D (1)(2) 0 D
    Common Stock 04/05/2024 D 190,000 D (1)(2) 0 I See footnote(3)
    Common Stock 04/05/2024 D 949,862 D (1)(2) 0 I See footnotes(4)(5)
    Common Stock 04/05/2024 D 2,650,177 D (1)(2) 0 I See footnote(6)
    Common Stock 04/05/2024 D 90,442 D (1)(2) 0 I See footnote(7)
    Common Stock 04/05/2024 D 11,103,333 D (1)(2) 0 I See footnote(8)
    Common Stock 04/05/2024 D 858,035 D (1)(2) 0 I See footnote(9)
    Common Stock 04/05/2024 D 968,990 D (1)(2) 0 I See footnote(10)
    Common Stock 04/05/2024 D 2,265,758 D (1)(2) 0 I See footnote(11)
    Common Stock 04/05/2024 D 1,298,908 D (1)(2) 0 I See footnote(12)
    Common Stock 04/05/2024 D 1,298,908 D (1)(2) 0 I See footnote(13)
    Common Stock 04/05/2024 D 100,000 D (1)(2) 0 I See footnote(14)
    Common Stock 04/05/2024 D 100,000 D (1)(2) 0 I See footnote(15)
    Common Stock 04/05/2024 J 1,000 A (16) 1,000 I See footnote(16)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.69(17) 04/05/2024 D 78,407 (17) 05/09/2033(17) Common Stock 78,407 (17) 0 D
    Stock Option (Right to Buy) $13.35(17) 04/05/2024 D 24,222 (17) 05/07/2032(17) Common Stock 24,222 (17) 0 D
    Stock Option (Right to Buy) $17.24(17) 04/05/2024 D 19,619 (17) 06/07/2031(17) Common Stock 19,619 (17) 0 D
    Stock Option (Right to Buy) $13.35(17) 04/05/2024 D 24,000 (17) 05/14/2029(17) Common Stock 24,000 (17) 0 D
    Stock Option (Right to Buy) $20.37(17) 04/05/2024 D 16,806 (17) 05/19/2030(17) Common Stock 16,806 (17) 0 D
    Explanation of Responses:
    1. On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN2)
    2. (cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.
    3. The securities were directly held by the David V. Goeddel and Alena Z. Goeddel 2004 Trust and the Alena Z. Goeddel Irrevocable Trust for which the Reporting Person and Alena Z. Goeddel serve as co-trustee.
    4. The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN5)
    5. (cont'd from FN 4) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    6. The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    7. The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    8. The securities were directly held by TCG LP. TCG GP is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are the Reporting Person, a member of the Issuer's board of directors, and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    9. The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    10. The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities
    11. The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    12. The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    13. The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    14. The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    15. The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
    16. At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
    17. Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share.
    /s/ James Evangelista, Attorney-in-fact 04/08/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NGM

    DatePrice TargetRatingAnalyst
    3/12/2024Outperform → Mkt Perform
    Raymond James
    2/28/2024Outperform → Market Perform
    TD Cowen
    2/27/2024Buy → Neutral
    Citigroup
    5/3/2023$6.00Buy
    Citigroup
    10/18/2022$29.00 → $4.00Buy → Neutral
    Goldman
    10/18/2022$42.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/17/2022Buy → Hold
    Jefferies
    10/17/2022Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $NGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:33:24 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:30:19 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:28:01 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NGM Biopharmaceuticals downgraded by Raymond James

      Raymond James downgraded NGM Biopharmaceuticals from Outperform to Mkt Perform

      3/12/24 7:29:29 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by TD Cowen

      TD Cowen downgraded NGM Biopharmaceuticals from Outperform to Market Perform

      2/28/24 6:43:03 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by Citigroup

      Citigroup downgraded NGM Biopharmaceuticals from Buy to Neutral

      2/27/24 8:54:39 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    SEC Filings

    See more
    • SEC Form 15-12G filed by NGM Biopharmaceuticals Inc.

      15-12G - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/15/24 7:57:22 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NGM Biopharmaceuticals Inc.

      EFFECT - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/9/24 12:15:15 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by NGM Biopharmaceuticals Inc.

      25-NSE - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 11:22:54 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tcg Opportunity Iii Gp, Llc returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:05:48 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group Gp, Lp returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:04:43 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:03:30 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NGM Bio Announces Closing of Tender Offer

      SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a

      4/5/24 9:19:51 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

      SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca

      3/19/24 5:30:44 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

      --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola

      3/11/24 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Financials

    Live finance-specific insights

    See more
    • NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

      Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy

      10/17/22 7:30:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. To access the live webcast and slides, please visit the "Investors & Media" section of NGM Bio's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. About NGM Bio NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives ha

      10/16/22 4:30:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 10:55:55 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/26/24 5:16:16 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/14/24 6:12:53 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Leadership Updates

    Live Leadership Updates

    See more
    • NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

      Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o

      5/4/23 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marathon Health Expands Board of Directors

      INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model.  Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti

      2/8/22 7:00:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

      Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN

      8/5/21 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care